Genzyme GENZ

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. New commercial chief at Prosensa

      Headlines

      Mon, 30 Jun 2014

      Prosensa Holding N.V. ( RNA ) hires Willem W. van Weperen as Chief Commercial Officer. Mr. van Weperen spent 15 years at Genzyme ( SNY ) in various senior management positions. Post your comment!

    2. Time To Buy Aastrom Biosciences

      Headlines

      Tue, 17 Jun 2014

      recently acquired Cell Therapy and Regenerative Medicine ("CTRM") business from Sanofi ( SNY ), previously known as Genzyme Biosurgery Aps. The deal closed on May 30, 2014. The deal came at a purchase price of $6.5 million, with $4.0

    3. New Morningstar Analyst Report for Biomarin Pharmaceutical Inc

      Stock Reports

      Fri, 2 May 2014

      of BioMarin's expertise. Viral contamination forced Genzyme (now Sanofi) to halt manufacturing of its enzyme replacement ..... disease therapies, and three products drive its sales. Genzyme (now part of Sanofi) markets Aldurazyme through its joint

    4. New Morningstar Analyst Report for Sanofi

      Stock Reports

      Fri, 14 Mar 2014

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    5. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      continues. I think there is going to be a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase

      Genzyme found at 3:20

      a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase growth and do
    6. Invest With These Exemplary Management Teams

      Headlines

      Sun, 26 May 2013

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    7. Sanofi's 4Q and 2013 Guidance Match Our Projections but Fall Short of Consensus Expectations

      Commentary

      Thu, 7 Feb 2013

      quarterly results. The company's updated guidance on an improving pipeline along with steady growth from emerging markets, Genzyme products, consumer health, vaccines, and diabetes drugs increases our conviction behind our wide moat rating for the

    8. Sanofi Posts Solid 3Q Supported by Cost-Containment Efforts, but No Change to Valuation

      Commentary

      Thu, 25 Oct 2012

      growth continued to perform well, with particular strength from diabetes drug Lantus, which was up 18% year over year. Genzyme products and emerging markets also continued to post steady gains. However, generic competition to cardiovascular drug

    9. RXL ProShares Ultra Health Care ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 18 Sep 2012

      Industries' TEVA acquisition of German generic drugmaker Ratiopharm Group International, Sanofi's SNY acquisition of Genzyme , Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals

    10. PPH Market Vectors Pharmaceutical ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 21 Aug 2012

      Industries' TEVA acquisition of German generic drug-maker Ratiopharm Group International, Sanofi's SNY acquisition of Genzyme , Merck of Germany's takeover of Millipore, and Pfizer's PFE acquisition of pain-drug maker King Pharmaceuticals

    « Prev12345Next »
    Content Partners